{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"14.200","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"871,970,522","primaryexch":"香港交易所","ric":"2142.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0037,"inline_upper_strike_price":"","sedol":"BN4GWL9","am":"115.02","iv":"","ew_strike":"","as":"14.010","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"14.000","registrar":"卓佳證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"1,000","update_time":"2025-09-28 00:06:03.0","lo52":"1.120","shares_issued_date":"2025年9月25日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"王勁松","underlying_ric":"2142.HK","hi52":"17.980","issuer_name":"和鉑醫藥控股有限公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"13.620","mkt_cap":"12.21","f_aum_hkd":null,"ew_sub_per_to":"","ls":"14.010","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.050","aum":"","issued_shares_class_B":null,"vo":"8.24","secondary_listing_flag":false,"listing_date":"2020年12月10日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"和鉑醫藥控股有限公司 - B","nm_s":"和鉑醫藥－Ｂ","sym":"2142","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"和鉑醫藥控股有限公司是一家主要從事腫瘤免疫學及免疫性疾病領域的創新療法開發業務的投資控股公司。該公司的產品包括HBM9161, HBM4003, HBM7008 and HBM1020。其中，巴託利單抗（HBM9161）主要用於免疫性血小板減少症、甲狀腺相關性眼病、重症肌無力、視神經脊髓炎譜系疾病等. 特那西普（HBM9036）主要用於乾眼病。此外，該公司還研究和開發腫瘤免疫產品管線，包括內部開發的新一代腫瘤免疫資產，針對治療免疫沙漠型、免疫排斥型及炎症型腫瘤。該公司擁有Harbour Mice平臺，該平臺能夠產生經典的雙重鏈雙輕鏈（H2L2）形式及僅重鏈（HCAb）形式的全人源單克隆抗體","op":"13.960","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港銅鑼灣<br/>希慎道33號<br/>利園一期<br/>19樓1918室","pc":"-0.36","days_to_expiry":null,"underlying_code":null,"pe":"488.15","eps_ccy":"USD","hdr":false,"launch_date":"","hc":"14.060","isin":"KYG4403H1002","moneyness":""}},"qid":"1759074137095"}
